Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab
- 14 June 2016
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (9), 2996-3003
- https://doi.org/10.1021/acs.molpharmaceut.6b00345
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug developmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published dataExperimental Eye Research, 2015
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular DegenerationOphthalmology, 2013
- Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population ApproachInvestigative Ophthalmology & Visual Science, 2013
- Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomersBiochimica et Biophysica Acta (BBA) - General Subjects, 2012
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III StudyOphthalmology, 2010
- Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical ConsiderationsToxicologic Pathology, 2008
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITSRetina, 2007
- Review: Practical Issues in Intravitreal Drug DeliveryJournal of Ocular Pharmacology and Therapeutics, 2001